Organon & (OGN) ZACKS·2025-01-30 23:56Group 1: Company Performance - Organon (OGN) closed at 0.87, indicating a 1.14% decrease from the same quarter last year [2] - The consensus estimate for revenue is $1.57 billion, down 1.69% from the prior-year quarter [2] Group 3: Analyst Estimates and Stock Performance - Recent changes to analyst estimates for Organon are crucial for investors, as positive revisions indicate optimism about the company's outlook [3] - The Zacks Rank system, which reflects these estimate changes, provides actionable ratings for investors [4] Group 4: Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 4 (Sell), with a 2.72% decrease in the consensus EPS estimate over the last 30 days [5] - The company has a Forward P/E ratio of 3.95, significantly lower than the industry average of 17.47, indicating it is trading at a discount [6] - Organon's PEG ratio is 0.83, compared to the Medical Services industry's average PEG ratio of 1.67 [6] Group 5: Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 150, placing it in the bottom 41% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]